Bicycle Therapeutics PLC (BCYC) — SEC Filings

Overview

Bicycle Therapeutics PLC (BCYC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 20, 2026: On April 20, 2026, Bicycle Therapeutics plc filed an 8-K report detailing other events. The filing includes financial statements and exhibits, with specific XBRL data files provided for enhanced transparency. The company's mailing and business addresses are located in Great Abington, Cambridge.

Sentiment Summary

Across 42 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 38 neutral. The dominant filing sentiment for Bicycle Therapeutics PLC is neutral.

Filing Type Overview

Bicycle Therapeutics PLC (BCYC) has filed 22 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13D/A, 5 SC 13G/A, 3 SC 13G with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (42)

• Bicycle Therapeutics Files 8-K Report — 8-K · Apr 20, 2026 Risk: low
  On April 20, 2026, Bicycle Therapeutics plc filed an 8-K report detailing other events. The filing includes financial statements and exhibits, with specific XBR
• Bicycle Therapeutics' Losses Widen on Soaring R&D Costs — 10-Q · Oct 30, 2025 Risk: high
  Bicycle Therapeutics plc reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $198.8 million, up from $117.2 milli
• Bicycle Therapeutics Announces Executive Changes and Board Appointments — 8-K · Sep 8, 2025 Risk: medium
  On September 8, 2025, Bicycle Therapeutics plc filed an 8-K report detailing the departure of Dr. Robert T. Drake as Chief Medical Officer and the appointment o
• Gilead to Acquire Bicycle Therapeutics for $1.5B — 8-K · Aug 8, 2025 Risk: medium
  Bicycle Therapeutics plc announced on August 6, 2025, that it has entered into a definitive agreement to be acquired by a subsidiary of Gilead Sciences, Inc. fo
• Bicycle Therapeutics' Q2 Loss Widens Amid R&D Spend — 10-Q · Aug 8, 2025 Risk: high
  Bicycle Therapeutics PLC reported a net loss of $44.6 million for the three months ended June 30, 2025, a significant increase from the $33.2 million net loss i
• Bicycle Therapeutics Files 8-K on Security Holder Vote — 8-K · Jun 17, 2025 Risk: low
  On June 17, 2025, Bicycle Therapeutics plc filed an 8-K report indicating a submission of matters to a vote of security holders. The filing does not contain spe
• Bicycle Therapeutics Files 8-K Report — 8-K · May 1, 2025 Risk: low
  On May 1, 2025, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, along w
• Bicycle Therapeutics Q1 2025: Revenue Up, Net Loss Continues — 10-Q · May 1, 2025 Risk: medium
  Bicycle Therapeutics plc filed a 10-Q for the period ending March 31, 2025. The company reported total assets of $690.6 million and total liabilities of $69.2 m
• Bicycle Therapeutics Files 8-K Report — 8-K · Apr 29, 2025 Risk: low
  On April 29, 2025, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate d
• Bicycle Therapeutics: Executive Compensation & Equity Awards Detailed — DEF 14A · Apr 23, 2025 Risk: low
  Bicycle Therapeutics plc filed a DEF 14A on April 23, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and equity a
• Bicycle Therapeutics Announces Director Changes and Compensation Updates — 8-K · Mar 27, 2025 Risk: low
  On March 21, 2025, Bicycle Therapeutics plc filed an 8-K report detailing several key events. These include the departure of director Dr. Jonathan M. Rothberg,
• Bicycle Therapeutics Files 8-K on Shareholder Nominations — 8-K · Mar 14, 2025 Risk: medium
  Bicycle Therapeutics plc filed an 8-K on March 14, 2025, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11 as of March 12, 2025. The filing
• Bicycle Therapeutics Files 8-K on Financials — 8-K · Feb 25, 2025 Risk: low
  On February 25, 2025, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
• Bicycle Therapeutics Files 2024 10-K — 10-K · Feb 25, 2025 Risk: medium
  Bicycle Therapeutics plc filed its 2024 10-K on February 25, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company
• Bicycle Therapeutics Files 8-K Report — 8-K · Jan 13, 2025 Risk: low
  On January 13, 2025, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and
• Baker Bros. Advisors Amends Bicycle Therapeutics Stake — SC 13D/A · Dec 17, 2024 Risk: medium
  Baker Bros. Advisors LP, through its affiliates, has amended its Schedule 13D filing regarding Bicycle Therapeutics plc as of December 17, 2024. The filing indi
• Bicycle Therapeutics Files 8-K — 8-K · Dec 13, 2024 Risk: low
  On December 13, 2024, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with n
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• Bicycle Therapeutics plc Files 8-K Report — 8-K · Oct 31, 2024 Risk: low
  On October 31, 2024, Bicycle Therapeutics plc filed an 8-K report detailing its financial results and operations. The filing includes financial statements and e
• Bicycle Therapeutics Files Q3 2024 10-Q — 10-Q · Oct 31, 2024 Risk: medium
  Bicycle Therapeutics plc filed a 10-Q for the period ending September 30, 2024. The company, based in Cambridge, UK, is in the pharmaceutical preparations indus
• Bicycle Therapeutics Files 8-K Report — 8-K · Oct 23, 2024 Risk: low
  On October 23, 2024, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicat
• Bicycle Therapeutics Files 8-K Report — 8-K · Sep 19, 2024 Risk: low
  On September 14, 2024, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material
• Bicycle Therapeutics Files 8-K on Financials — 8-K · Aug 6, 2024 Risk: low
  On August 6, 2024, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Bicycle Therapeutics Q2 2024 Update — 10-Q · Aug 6, 2024 Risk: medium
  Bicycle Therapeutics plc filed a 10-Q for the period ending June 30, 2024. The company reported on its financial performance and business activities, including
• Bicycle Therapeutics Terminates Material Definitive Agreement — 8-K · Jul 10, 2024 Risk: medium
  Bicycle Therapeutics plc announced on July 9, 2024, the termination of a material definitive agreement. The company, incorporated in England and Wales, filed th
• Bicycle Therapeutics Files 8-K Report — 8-K · Jun 18, 2024 Risk: low
  On June 18, 2024, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating
• SC 13G Filing — SC 13G · Jun 7, 2024
• Baker Bros. Advisors Ups Stake in Bicycle Therapeutics — SC 13D/A · May 28, 2024 Risk: medium
  Baker Bros. Advisors LP, through its affiliates, has amended its Schedule 13D filing concerning Bicycle Therapeutics plc. As of May 28, 2024, Baker Bros. Adviso
• Bicycle Therapeutics Announces Material Definitive Agreement — 8-K · May 23, 2024 Risk: medium
  Bicycle Therapeutics plc announced on May 23, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equit
• Bicycle Therapeutics Files 8-K on Security Holder Vote Matters — 8-K · May 16, 2024 Risk: low
  On May 16, 2024, Bicycle Therapeutics plc filed an 8-K report indicating a submission of matters to a vote of security holders. The company, incorporated in Eng
• Bicycle Therapeutics Files 8-K on Financials — 8-K · May 2, 2024 Risk: low
  Bicycle Therapeutics plc filed an 8-K on May 2, 2024, reporting on its results of operations and financial condition. The filing includes financial statements a
• Bicycle Therapeutics plc Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk: low
  BICYCLE THERAPEUTICS plc (BCYC) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Bicycle Therapeutics plc filed a 10-Q report for the period ending
• Bicycle Therapeutics Reports Material Agreement and Officer Changes — 8-K · Apr 18, 2024 Risk: medium
  On April 16, 2024, Bicycle Therapeutics plc entered into a material definitive agreement. The company also reported the departure of directors or certain office
• Bicycle Therapeutics plc Schedules 2024 Annual General Meeting — DEF 14A · Apr 15, 2024 Risk: BCYC
  BICYCLE THERAPEUTICS plc (BCYC) filed a Proxy Statement (DEF 14A) with the SEC on April 15, 2024. The 2024 Annual General Meeting (AGM) for Bicycle Therapeutics
• Bicycle Therapeutics Files 8-K on Operations, Officer Changes — 8-K · Feb 20, 2024 Risk: low
  Bicycle Therapeutics plc filed an 8-K on February 20, 2024, reporting on its financial condition and operations. The filing also addressed the departure or appo
• Bicycle Therapeutics plc Files 2023 Annual Report on Form 10-K — 10-K · Feb 20, 2024 Risk: medium
  BICYCLE THERAPEUTICS plc (BCYC) filed a Annual Report (10-K) with the SEC on February 20, 2024. Bicycle Therapeutics plc filed its 2023 Form 10-K on February 20
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Janus Henderson Group Maintains Significant Stake in Bicycle Therapeutics — SC 13G/A · Feb 12, 2024 Risk: low
  Janus Henderson Group plc, a major investment firm, filed an amended SC 13G/A on February 12, 2024, disclosing its ownership of American Depositary Shares in Bi
• Baker Bros. Advisors LP Discloses Significant Stake in Bicycle Therapeutics — SC 13G · Feb 12, 2024 Risk: low
  Baker Bros. Advisors LP, a prominent investment firm, filed an SC 13G on February 12, 2024, disclosing its ownership of Ordinary Shares in Bicycle Therapeutics

Related Companies

GILD

Frequently Asked Questions